Cancer & Disease Research Sponsored by Beckman Coulter
New platform includes biological similarities to accelerate drug discovery
A new open-access tool provides information on the effects of nearly 1 million compounds in a wide range of biological settings. The new tool, published in Nature Biotechnology on May 18, may change the drug discovery process by moving beyond reliance on chemical information alone.  Discuss
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines, according to a new study. The findings were published in Nature on May 18.  Discuss
Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents the SARS-CoV-2 virus from infecting cultured cells. Authored by a team of researchers from Utrecht University, Erasmus Medical Center, and Harbour BioMed, the report was published in Nature Communications on May 4.  Discuss
Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene therapy, according to a new review article published April 24 in Frontiers in Microbiology.  Discuss
Directed evolution shows promise in reducing drug discovery times
A research collaboration between scientists at the University of Leeds and AstraZeneca resulted in the development of a technique that can significantly reduce the discovery time for possible new antibody-based therapies. The approach, published in Nature Communications on April 14, shows how protein fragments can be screened for susceptibility to aggregation in early drug discovery.  Discuss
3 reasons the coronavirus outbreak has been so severe
WASHINGTON, DC - Why has the current outbreak of coronavirus been so severe compared with past epidemics of viral respiratory diseases? It has to do with unique characteristics of the coronavirus itself, according to a speaker at a February 26 congressional briefing.  Discuss
Genetically engineered probiotics successfully deliver immunotherapies
A new technology enables genetically engineered probiotic bacteria to be used as an efficacious, stable, and safe platform to deliver immunotherapies directly into a variety of tumors in just a single dose. The research was published online on February 12 in Science Translational Medicine.  Discuss
Microscopy with fluorescent tags gives high-def view of diabetes-related proteins
Leveraging the power of new imaging techniques, scientists are using unique fluorescent tags in combination with superresolution microscopy to gain novel insights into a receptor that plays a key role in controlling blood sugar levels. These insights will open the door to improved treatment options for type 2 diabetes.  Discuss
Better flu treatments on the way thanks to the discovery of broadly protective antibodies
Research from the National Institutes of Allergy and Infectious Diseases (NIAID) isolated the antibodies from a person sick with the flu five days after onset. They isolated antibodies that bind to neuraminidase (NA) proteins on the surface of influenza viruses, which provided broad protection against several different strains of influenza both in vitro and in vivo. The researchers provided characterization details in the October 25 issue of Science.  Discuss
Success of immunotherapies increased in cancer patients through co-treatment with monoclonal antibodies
A new approach provides evidence that it is possible to break down the protective wall surrounding tumor cells, therefore making immunotherapies more effective in patients with a variety of cancers. This research, funded by Cancer Research UK, was published in the EBioMedicine on August 25th.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter